Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?

Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy

(2009) Pamela A Moise et al.   ANNALS OF PHARMACOTHERAPY

Safety of High‐Dose Intravenous Daptomycin Treatment: Three‐Year Cumulative Experience in a Clinical Program

(2009) D. A. Figueroa et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter‐Related Infection: 2009 Update by the Infectious Diseases Society of America

(2009) Leonard A. Mermel et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008)

(2009) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin® Outcomes Registry and Experience (CORE)

(2009) John F. Mohr et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?

(2009) V. Mave et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Daptomycin Therapy for Vancomycin-Resistant Enterococcal Bacteremia: A Retrospective Case Series of 30 Patients

(2009) Jason C Gallagher et al.   PHARMACOTHERAPY

Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

(2007) A. Soriano et al.   CLINICAL INFECTIOUS DISEASES